Labcorp Launches New Non-Invasive MASH Diagnostic Test via OnDemand Platform
LH is trading near its 52-week low of $241.81 (8.9% above the low) on light trading volume (0.2× avg).
Summary
Labcorp has launched NASHnext®, a new non-invasive diagnostic test for at-risk MASH (Metabolic dysfunction-Associated SteatoHepatitis), powered by GENFIT's NIS4® technology. The test is now available through Labcorp's OnDemand platform, significantly expanding patient access. This new offering addresses a major diagnostic gap for a highly prevalent condition, with a potential U.S. patient population in the high tens of millions. This commercialization effort could contribute meaningfully to Labcorp's diagnostics revenue, building on recent strong Q1 results. Adoption rates and future reimbursement decisions will be critical to watch.
At the time of this announcement, LH was trading at $263.22 on NYSE in the Life Sciences sector, with a market capitalization of approximately $21.6B. The 52-week trading range was $241.81 to $293.72. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.